Xeroderma Pigmentosum Group A Promotes Autophagy to Facilitate Cisplatin Resistance in Melanoma Cells through the Activation of PARP1

Journal of Investigative Dermatology

Volumn 136, Issue 6, 2016, Pages 1219-1228

  Ge, Rui ^a   Liu, Lin ^a   Dai, Wei ^a   Zhang, Weigang ^a   Yang, Yuqi ^a   Wang, Huina ^a   Shi, Qiong ^a   Guo, Sen ^a   Yi, Xiuli ^a   Wang, Gang ^a   Gao, Tianwen ^a   Luan, Qi ^a   Li, Chunying ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; DNA BINDING PROTEIN; PARPBP PROTEIN, HUMAN; XERODERMA PIGMENTOSUM GROUP A PROTEIN;

ARTICLE; AUTOPHAGY; CONTROLLED STUDY; DNA REPAIR; DRUG RESISTANCE; HUMAN; HUMAN CELL; MELANOMA CELL; PRIORITY JOURNAL; XERODERMA PIGMENTOSUM; APOPTOSIS; CELL CULTURE; COMPARATIVE STUDY; CYTOLOGY; DNA DAMAGE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; MELANOCYTE; MELANOMA; METABOLISM; SKIN NEOPLASMS; TUMOR CELL CULTURE;

APOPTOSIS; AUTOPHAGY; CELLS, CULTURED; CISPLATIN; DNA DAMAGE; DNA REPAIR; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOCYTES; MELANOMA; SKIN NEOPLASMS; TUMOR CELLS, CULTURED; XERODERMA PIGMENTOSUM; XERODERMA PIGMENTOSUM GROUP A PROTEIN;

EID: 84978437302     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1016/j.jid.2016.01.031     Document Type: Article

References (41)

1. Bixel, K., Hays, J.L., Olaparib in the management of ovarian cancer. Pharmgenomics Pers Med 8 (2015), 127–135.
2. Bradbury, P.A., Middleton, M.R., DNA repair pathways in drug resistance in melanoma. Anticancer Drugs 15 (2004), 421–426.
3. Camenisch, U., Dip, R., Schumacher, S.B., Schuler, B., Naegeli, H., Recognition of helical kinks by xeroderma pigmentosum group A protein triggers DNA excision repair. Nat Struct Mol Biol 13 (2006), 278–284.
4. Cummings, M., Higginbottom, K., McGurk, C.J., Wong, O.G., Koberle, B., Oliver, R.T., et al. XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: role of ERCC1 in homologous recombination repair. Biochem Pharmacol 72 (2006), 166–175.
5. Czarny, P., Pawlowska, E., Bialkowska-Warzecha, J., Kaarniranta, K., Blasiak, J., Autophagy in DNA damage response. Int J Mol Sci 16 (2015), 2641–2662.
6. Del Bollo, B., Toscano, M., Moretti, D., Maellaro, E., Cisplatin-induced apoptosis inhibits autophagy, which acts as a pro-survival mechanism in human melanoma cells. PLoS One, 8, 2013, e57236.
7. Eggermont, A.M., Spatz, A., Robert, C., Cutaneous melanoma. Lancet 383 (2014), 816–827.
8. Fang, E.F., Scheibye-Knudsen, M., Brace, L.E., Kassahun, H., SenGupta, T., Nilsen, H., et al. Defective mitophagy in XPA via PARP-1 hyperactivation and NAD(+)/SIRT1 reduction. Cell 157 (2014), 882–896.
9. Farmer, H., McCabe, N., Lord, C.J., Tutt, A.N., Johnson, D.A., Richardson, T.B., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 (2005), 917–921.
10. Feng, F.Y., de Bono, J.S., Rubin, M.A., Knudsen, K.E., Chromatin to clinic: the molecular rationale for PARP1 inhibitor function. Mol Cell 58 (2015), 925–934.
11. Fischer, J.M., Popp, O., Gebhard, D., Veith, S., Fischbach, A., Beneke, S., et al. Poly(ADP-ribose)-mediated interplay of XPA and PARP1 leads to reciprocal regulation of protein function. FEBS J 281 (2014), 3625–3641.
12. Flaherty, K.T., Lee, S.J., Zhao, F., Schuchter, L.M., Flaherty, L., Kefford, R., et al. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol 31 (2013), 373–379.
13. Fu, X., Hu, J., Han, H.Y., Hua, Y.J., Zhou, L., Shuai, W.D., et al. High expression of XPA confers poor prognosis for nasopharyngeal carcinoma patients treated with platinum-based chemoradiotherapy. Oncotarget 6 (2015), 28478–28490.
14. Galluzzi, L., Vitale, I., Michels, J., Brenner, C., Szabadkai, G., Harel-Bellan, A., et al. Systems biology of cisplatin resistance: past, present and future. Cell Death Dis, 5, 2014, e1257.
15. Hatch, S.B., Swift, L.P., Caporali, S., Carter, R., Hill, E.J., MacGregor, T.P., et al. XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: suitability as a biomarker for patient selection. Int J Cancer 134 (2014), 1495–1503.
16. He, J., Yu, J.J., Xu, Q., Wang, L., Zheng, J.Z., Liu, L.Z., et al. Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy. Autophagy 11 (2015), 373–384.
17. Huang, J., Liu, K., Yu, Y., Xie, M., Kang, R., Vernon, P., et al. Targeting HMGB1-mediated autophagy as a novel therapeutic strategy for osteosarcoma. Autophagy 8 (2012), 275–277.
18. Janku, F., McConkey, D.J., Hong, D.S., Kurzrock, R., Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol 8 (2011), 528–539.
19. Kenific, C.M., Debnath, J., Cellular and metabolic functions for autophagy in cancer cells. Trends Cell Biol 25 (2015), 37–45.
20. King, B.S., Cooper, K.L., Liu, K.J., Hudson, L.G., Poly(ADP-ribose) contributes to an association between poly(ADP-ribose) polymerase-1 and xeroderma pigmentosum complementation group A in nucleotide excision repair. J Biol Chem 287 (2012), 39824–39833.
21. Lin, J., Huang, Z., Wu, H., Zhou, W., Jin, P., Wei, P., et al. Inhibition of autophagy enhances the anticancer activity of silver nanoparticles. Autophagy 10 (2014), 2006–2020.
22. Liu, L., Yang, M., Kang, R., Wang, Z., Zhao, Y., Yu, Y., et al. HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells. Leukemia 25 (2011), 23–31.
23. Liu, Y., Bernauer, A.M., Yingling, C.M., Belinsky, S.A., HIF1α regulated expression of XPA contributes to cisplatin resistance in lung cancer. Carcinogenesis 33 (2012), 1187–1192.
24. McNeil, E.M., Astell, K.R., Ritchie, A.M., Shave, S., Houston, D.R., Bakrania, P., et al. Inhibition of the ERCC1-XPF structure-specific endonuclease to overcome cancer chemoresistance. DNA Repair (Amst) 31 (2015), 19–28.
25. Megahed, A.I., Koon, H.B., What is the role of chemotherapy in the treatment of melanoma?. Curr Treat Options Oncol 15 (2014), 321–335.
26. Mukhopadhyay, S., Das, D.N., Panda, P.K., Sinha, N., Naik, P.P., Bissoyi, A., et al. Autophagy protein Ulk1 promotes mitochondrial apoptosis through reactive oxygen species. Free Radic Biol Med 89 (2015), 311–321.
27. Munoz-Gamez, J.A., Rodriguez-Vargas, J.M., Quiles-Perez, R., Aguilar-Quesada, R., Martin-Oliva, D., de Murcia, G., et al. PARP-1 is involved in autophagy induced by DNA damage. Autophagy 5 (2009), 61–74.
28. O'Donovan, T.R., O'Sullivan, G.C., McKenna, S.L., Induction of autophagy by drug-resistant esophageal cancer cells promotes their survival and recovery following treatment with chemotherapeutics. Autophagy 7 (2011), 509–524.
29. Ordureau, A., Sarraf, S.A., Duda, D.M., Heo, J.M., Jedrychowski, M.P., Sviderskiy, V.O., et al. Quantitative proteomics reveal a feedforward mechanism for mitochondrial PARKIN translocation and ubiquitin chain synthesis. Mol Cell 56 (2014), 360–375.
30. Rademakers, S., Volker, M., Hoogstraten, D., Nigg, A.L., Mone, M.J., Van Zeeland, A.A., et al. Xeroderma pigmentosum group A protein loads as a separate factor onto DNA lesions. Mol Cell Biol 23 (2003), 5755–5767.
31. Sandhu, S.K., Yap, T.A., de Bono, J.S., Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. Eur J Cancer 46 (2010), 9–20.
32. Song, L., Ritchie, A.M., McNeil, E.M., Li, W., Melton, D.W., Identification of DNA repair gene Ercc1 as a novel target in melanoma. Pigment Cell Melanoma Res 24 (2011), 966–971.
33. Steffen, J.D., Brody, J.R., Armen, R.S., Pascal, J.M., Structural implications for selective targeting of PARPs. Front Oncol, 3, 2013, 301.
34. Stewart, D.J., Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 63 (2007), 12–31.
35. Sui, X., Chen, R., Wang, Z., Huang, Z., Kong, N., Zhang, M., et al. Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis, 4, 2013, e838.
36. Tanida, I., Autophagosome formation and molecular mechanism of autophagy. Antioxid Redox Signal 14 (2011), 2201–2214.
37. Wu, X., Fan, W., Xu, S., Zhou, Y., Sensitization to the cytotoxicity of cisplatin by transfection with nucleotide excision repair gene xeroderma pigmentosun group A antisense RNA in human lung adenocarcinoma cells. Clin Cancer Res 9 (2003), 5874–5879.
38. Yang, M., Liu, L., Xie, M., Sun, X., Yu, Y., Kang, R., et al. Poly-ADP-ribosylation of HMGB1 regulates TNFSF10/TRAIL resistance through autophagy. Autophagy 11 (2015), 214–224.
39. Yu, L., Gu, C., Zhong, D., Shi, L., Kong, Y., Zhou, Z., et al. Induction of autophagy counteracts the anticancer effect of cisplatin in human esophageal cancer cells with acquired drug resistance. Cancer Lett 355 (2014), 34–45.
40. Zeng, X., Yan, T., Schupp, J.E., Seo, Y., Kinsella, T.J., DNA mismatch repair initiates 6-thioguanine–induced autophagy through p53 activation in human tumor cells. Clin Cancer Res 13 (2007), 1315–1321.
41. Zhou, J., Ng, S., Huang, Q., Wu, Y.T., Li, Z., Yao, S.Q., et al. AMPK mediates a pro-survival autophagy downstream of PARP-1 activation in response to DNA alkylating agents. FEBS Lett 587 (2013), 170–177.